CG Oncology Director Leonard Post Exercises Options and Sells Shares Under 10b5-1 Plan

CG Oncology, Inc. director Leonard E. Post filed a Form 4 disclosing significant stock transactions on June 22, 2026. Post exercised 5,000 stock options at $0.60 per share, acquiring 5,000 shares of common stock. On the same day, he sold all 5,000 shares at $65.00 per share, realizing substantial gains. The sale was executed pursuant to a Rule 10b5-1 trading plan adopted on March 5, 2026, which provides an affirmative defense against insider trading allegations. Following these transactions, Post holds 111,077 stock options expiring July 8, 2028, but no longer holds any common stock directly. The transactions demonstrate significant appreciation in CG Oncology's stock price from the $0.60 option exercise price to the $65.00 sale price.